MARKET NEWS

BioXcel Therapeutics Announces Addition of Merck KGaA & Pfizer to Clinical Collaboration With Nektar  
Aptose Biosciences & CrystalGenomics Announce Issuance of Patent for Oral Small Molecule
ContraFect Announces $6.94 Million in Funding from CARB-X
Lipomedix Announces Initiation of Phase 1b Trial
Apellis Resumes Dosing in Its Phase 3 Program for Patients With Geographic Atrophy
Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

 

 

Hovione offers customized services and innovative solutions from drug substance to drug product with high standards of quality and technical expertise. We provide reliable supply with flexible manufacturing to bring medicines to market faster. Utilizing innovative technologies and methodologies, and with a global footprint, Hovione is an integrated supplier to the pharmaceutical industry having the privilege of serving patients. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Procarta Announces Significant Investment for New Class of Antibiotics

Procarta Announces Significant Investment for New Class of Antibiotics

Procarta Biosystems recently announced $1.7 million of new funding from the Novo Holdings REPAIR Impact Fund to support development of novel therapies to combat antimicrobial resistance (AMR).

Biogen Announces Agreement to Acquire Nightstar Therapeutics

Biogen Announces Agreement to Acquire Nightstar Therapeutics

Biogen recently announced it has entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.

Catalent Invests Over  Million to Commercialize ODT Technology

Catalent Invests Over $27 Million to Commercialize ODT Technology

Catalent Pharma Solutions recently announced that it is to invest more than $27 million to commercialize its next-generation oral disintegrating tablet (ODT) technology, Zydis Ultra.

Nemera’s Preservative-Free Multidose Eye Dropper Approved for Santen’s Drug in 29 European Countries

Nemera’s Preservative-Free Multidose Eye Dropper Approved for Santen’s Drug in 29 European Countries

Nemera recently announce its multidose eye dropper Novelia has been approved for the preservative-free formulation Cosopt iMulti (20 mg/ml dorzolamide + 5 mg/ml timolol eye drops, solution).

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 20 – Analytical Instruments
March 27 – Parenteral Contract Manufacturing